MannKind | MNKD - SCHULD





SCHULD Veränderung Datum
Adma Biologics USD 204.41M 121.28M 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Eli Lilly USD 43.37B 867M 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Insmed USD 725.8M 1.82M 2026-06
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 36.51M 500K 2026-03
MannKind USD 330.96M 36.48M 2026-03
Merck USD 49.12B 222M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Novavax USD 233.31M 4.23M 2024-09
Novo Nordisk DKK 146.38B 27.66B 2026-03
Pfizer USD 63.19B 536M 2026-06
Sanofi EUR 23.58B 3.56B 2026-06
Xencor USD 175.16M 12.58M 2026-03